Table 2 Current LTP and STP treatment by country
Treatment,a n (%) | AU (n = 28) | AT (n = 13) | CA (n = 32) | FR (n = 58) | DE (n = 7) | ES (n = 39) | CH (n = 8) | UK (n = 57) |
|---|---|---|---|---|---|---|---|---|
LTP | n = 22 | n = 2 | n = 23 | n = 35 | n = 1 | n = 28 | n = 2 | n = 38 |
Cinryze® (C1 esterase inhibitor [human]) | – | 1 (50.0) | 4 (17.4) | 7 (20.0) | 1 (100.0) | 1 (3.6) | – | 8 (21.1) |
Berinert® (C1 esterase inhibitor [human]) | 10 (45.5) | – | 16 (69.6) | 2 (5.7) | – | 7 (25.0) | 1 (50.0) | 13 (34.2) |
Lysteda® (tranexamic acid) | – | – | 3 (13.0) | 2 (5.7) | – | 2 (7.1) | – | 12 (31.6) |
Tranexamic acid | 8 (36.4) | – | – | – | – | – | – | – |
Azol®/danazol | 9 (40.9) | – | 1 (4.3) | 15 (42.9) | – | 11 (39.3) | – | 7 (18.4) |
Winstrol® (stanozolol) | – | – | – | – | – | 10 (35.7) | – | 1 (2.6) |
Oxandrin® (oxandrolone) | – | – | – | – | – | – | – | 1 (2.6) |
Other | – | 1 (50.0) | 3 (13.0) | 15 (42.9) | – | 1 (3.6) | 1 (50.0) | 4 (10.5) |
STP | n = 18 | n = 8 | n = 21 | n = 30b | n = 6 | n = 30 | n = 4 | n = 39 |
Cinryze® (C1 esterase inhibitor [human]) | 1 (5.6) | 2 (25.0) | 2 (9.5) | 4 (13.3) | 1 (16.7) | 5 (16.7) | – | 7 (17.9) |
Berinert® (C1 esterase inhibitor [human]) | 13 (72.2) | 6 (75.0) | 18 (85.7) | 11 (36.7) | 5 (83.3) | 19 (63.3) | 4 (100.0) | 28 (71.8) |
Lysteda® (tranexamic acid) | – | – | 2 (9.5) | 1 (3.3) | – | 1 (3.3) | – | 3 (7.7) |
Tranexamic acid | 1 (5.6) | – | – | – | – | – | – | – |
Azol®/danazol | 6 (33.3) | – | 1 (4.8) | 13 (43.3) | – | 8 (26.7) | – | 3 (7.7) |
Winstrol® (stanozolol) | – | – | – | – | – | 4 (13.3) | – | – |
Other | 2 (11.1) | – | – | – | – | – | – | – |